Literature DB >> 22577802

Toll-like receptor 7 agonist, imiquimod, inhibits oral squamous carcinoma cells through apoptosis and necrosis.

Mee-Young Ahn1, Seong-Min Kwon, Hak Hyun Cheong, Jong-Hwan Park, Jun Lee, Seung-Ki Min, Sang-Gun Ahn, Jung-Hoon Yoon.   

Abstract

BACKGROUND: Toll-like receptor (TLR) agonists have anticancer effect by inducing apoptosis or activating immune cells. In this study, we investigated whether imiquimod, TLR7 agonist, inhibits the proliferation of oral cancer cells.
METHODS: Toll-like receptor 7 expression and IL-6/8 production by imiquimod were examined using RT-PCR and Enzyme-linked immunosorbent assay, respectively. Cell viability was examined by MTT assay. To examine apoptotic cell death, Annexin V/PI staining for flow cytometry and Western blot analysis were performed. Necrotic cell death was determined by leakage of lactate dehydrogenase (LDH), HMGB1, and PI staining in imiquimod-treated oral squamous cell carcinoma (OSCC) cells.
RESULTS: Toll-like receptor 7 mRNA was expressed in OSCC cells. Imiquimod induced IL-6 and IL-8 production in OSCC cells, suggesting the functional expression of TLR7. Imiquimod inhibited cells proliferation in a dose-dependent manner. The ratio of annexin V-positive cells and cleaved caspase-3/7 was increased by imiquimod treatment in OSCC cells, suggesting that imiquimod-induced cell death in OSCC cells may be owing to apoptosis. In addition, LDH secretion and PI staining were detected in OSCC cells treated with imiquimod, showing that imiquimod also induced necrotic cell death in the OSCC cells.
CONCLUSIONS: Imiquimod inhibited effectively the growth of OSCC cells by inducing apoptosis and necrosis.
© 2012 John Wiley & Sons A/S.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22577802     DOI: 10.1111/j.1600-0714.2012.01158.x

Source DB:  PubMed          Journal:  J Oral Pathol Med        ISSN: 0904-2512            Impact factor:   4.253


  19 in total

Review 1.  Microbial Nucleic Acid Sensing in Oral and Systemic Diseases.

Authors:  K E Crump; S E Sahingur
Journal:  J Dent Res       Date:  2015-10-05       Impact factor: 6.116

2.  Association of single-nucleotide polymorphisms of high-mobility group box 1 with susceptibility and clinicopathological characteristics of uterine cervical neoplasia in Taiwanese women.

Authors:  Hsin-Hung Wu; Yu-Fan Liu; Shun-Fa Yang; Wea-Lung Lin; Shiuan-Chih Chen; Chih-Ping Han; Hsiang-Ling Wang; Long-Yau Lin; Po-Hui Wang
Journal:  Tumour Biol       Date:  2016-10-04

3.  Expression of toll-like receptors in HPV-positive and HPV-negative oropharyngeal squamous cell carcinoma--an in vivo and in vitro study.

Authors:  Lauri Jouhi; Neeta Datta; Suvi Renkonen; Timo Atula; Antti Mäkitie; Caj Haglund; Abdirisak Ahmed; Stina Syrjänen; Reidar Grénman; Eeva Auvinen; Sanna Lehtonen; Jaana Hagström
Journal:  Tumour Biol       Date:  2015-05-05

4.  Dual activation of Toll-like receptors 7 and 9 impairs the efficacy of antitumor vaccines in murine models of metastatic breast cancer.

Authors:  Mariela A Moreno Ayala; María Florencia Gottardo; María Soledad Gori; Alejandro Javier Nicola Candia; Carla Caruso; Andrea De Laurentiis; Mercedes Imsen; Slobodanka Klein; Elisa Bal de Kier Joffé; Gabriela Salamone; Maria G Castro; Adriana Seilicovich; Marianela Candolfi
Journal:  J Cancer Res Clin Oncol       Date:  2017-04-21       Impact factor: 4.553

Review 5.  Chemokine function in periodontal disease and oral cavity cancer.

Authors:  Sinem Esra Sahingur; W Andrew Yeudall
Journal:  Front Immunol       Date:  2015-05-05       Impact factor: 7.561

Review 6.  Trial Watch: Toll-like receptor agonists for cancer therapy.

Authors:  Erika Vacchelli; Alexander Eggermont; Catherine Sautès-Fridman; Jérôme Galon; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2013-06-10       Impact factor: 8.110

7.  Combinations of TLR ligands: a promising approach in cancer immunotherapy.

Authors:  Saskia Stier; Claudia Maletzki; Ulrike Klier; Michael Linnebacher
Journal:  Clin Dev Immunol       Date:  2013-11-25

Review 8.  Toll-like receptors and cancer, particularly oral squamous cell carcinoma.

Authors:  Alison Mary Rich; Haizal Mohd Hussaini; Venkata P B Parachuru; Gregory J Seymour
Journal:  Front Immunol       Date:  2014-09-24       Impact factor: 7.561

9.  Effects of HMGB1 Polymorphisms on the Susceptibility and Progression of Hepatocellular Carcinoma.

Authors:  Bin Wang; Chao-Bin Yeh; Ming-Yu Lein; Chen-Ming Su; Shun-Fa Yang; Yu-Fan Liu; Chih-Hsin Tang
Journal:  Int J Med Sci       Date:  2016-04-09       Impact factor: 3.738

Review 10.  Immunomodulatory and antitumor effects of type I interferons and their application in cancer therapy.

Authors:  Ruan F V Medrano; Aline Hunger; Samir Andrade Mendonça; José Alexandre M Barbuto; Bryan E Strauss
Journal:  Oncotarget       Date:  2017-07-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.